Jeesun Yoon

Seoul National University Hospital

H指数:8

被引数:330

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

From screening to surveillance: integrated prevention of Helicobacter pylori–associated gastric cancer in the Asia-Pacific region

从筛查到监测：亚太地区幽门螺杆菌相关胃癌的综合预防

Lancet Regional Health-Western Pacific

IF8.1

2026-08-170

OAAI

Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy

胆道癌患者接受度伐利尤米为基础化疗时，影像学检测的免疫相关不良事件预测价值

European Radiology

IF4.7

2026-05-280

OAAI

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial

新辅助FOLFIRINOX在可切除胰腺癌中的疗效（NeoFOL-R）：一项国际、多中心、前瞻性、随机对照试验的研究方案

BMC Cancer

IF3.4

2026-02-240

OAAI

Hye-Sol Jung; Julian Choi; Se Jun Park; Youngmin Han; Young Jae Cho; Jeesun Yoon; Do-Youn Oh; Yoo-Seok Yoon; Jin Won Kim; Chang-Sup Lim; Jin Hyun Park; In Sil Choi; Tae Ho Hong; Hyung Sun Kim; Hei-Cheul Jeung; Keun Soo Ahn; Jin Young Kim; Young-Dong Yu; Ju Won Kim; Ho Kyoung Hwang; Choong-kun Lee; Hye Jin Choi; Yun Kyung Jung; Kwonoh Park; Jai Hoon Yoon; In Woong Han; Jung Yong Hong; Hyung Il Seo; Jae Do Yang; So-Yeon Jeon; Seok Jeong Yang; Hong Jae Chon; Wooil Kwon; Joon Seong Park; Yan-Shen Shan; Myung Ah Lee; Jin-Young Jang

Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer

开放标签、单臂、II期试验，旨在研究sitravatinib联合tislelizumab方案作为晚期胆道癌二线治疗的疗效。

Journal of Hepatology

IF33

2025-11-240

OAAI

An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer

评估一种新型抗HER2双-paratopic抗体zanidatamab，用于治疗胆道癌

Expert Opinion on Biological Therapy

IF4

2025-09-060

PRE